Caveolins and lung function

Advances in Experimental Medicine and Biology

Volumn 729, Issue , 2012, Pages 157-179

  Maniatis, Nikolaos A ^a   Chernaya, Olga ^b   Shinin, Vasily ^b   Minshall, Richard D ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN; CAVEOLIN 1; CAVEOLIN 2; MESSENGER RNA;

ARTICLE; CAVEOLA; CAVEOLIN 1 GENE; CAVEOLIN 2 GENE; CELL SPECIFICITY; DISEASE ASSOCIATION; DOWN REGULATION; GENE; GENE DELETION; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATORY DISEASE; LUNG ALVEOLUS EPITHELIUM; LUNG CARCINOGENESIS; LUNG DEVELOPMENT; LUNG ENDOTHELIUM; LUNG FIBROSIS; LUNG FUNCTION; MOLECULAR PATHOLOGY; NONHUMAN; OBSTRUCTIVE AIRWAY DISEASE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION;

ANIMALS; CAVEOLINS; ENDOTHELIUM; HUMANS; LUNG; LUNG DISEASES; PULMONARY ALVEOLI;

MAMMALIA; MUS;

EID: 84859799550     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-1222-9_11     Document Type: Article

References (170)

1. West JB, Watson RR, Fu Z. The human lung: Did evolution get it wrong? Eur Respir J 2007; 29(1): 11-17.
2. West JB. Thoughts on the pulmonary blood-gas bather. Am J Physiol Lung Cell Mol Physiol 2003; 285(3):L501-L5 13.
3. Gehr P, Bachofen M, Weibel ER. The nomial human lung: Ultrastructure and morphometric estimation of diffusion capacity. Respir Physiol 1978; 32(2):121-140.
4. Phillips CO, Kaye SR. On the asymmetry of bifurcations in the bronchial tree. RespirPhysiol 1997; 107(1):85-98.
5. Stevens I, Phan S, Frid MG et al. Lung vascular cell heterogeneity: Endothelium, smooth muscle, and fibroblasts. Proc Am Thorac Soc 2008; 5(7):783-791.
6. Whitsett JA, Wert SE, Weaver TE. Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med 2010; 61:105-119.
7. Gosens R, Mutawe M, Martin S et al. Caveolae and caveolins in the respiratory system. Curr Mol Med 2008; 8(8):741-753.
8. Anderson RO. The caveolae membrane system. Annu Rev Biochem 1998; 67:199-225.
9. Couet J, Li S, Okamoto T et al. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins.J Biol Chem 1997;272(10):6525-6533.
10. Li S, Couet J, Lisanti MP. Src tyrosine kinases, Gaipha subunits and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem 1996; 271(46):29182-29190.
11. Razani B, Lisanti MP. Caveolin-deficient mice: Insights into caveolar function human disease. J Clin Invest 2001; 108(11):1553-1561.
12. Monisey EE, Hogan BL. Preparing for the firstbreath: Genetic and cellularmechanisms in lung development. Dcv Cell 18(1):8-23.
13. Schwarz MA, Caldwell L, Cafasso D et al. Emerging pulmonary vasculature lacks fate specification. Am J Physiol Lung Cell Mol Physiol 2009; 296(1):L71-L81.
14. Ramirez MI, Pollack L, Millien Octal. The alpha-isoform of caveolin-1 is a marker of vasculogenesis in early lung development. J Histochem Cytochem 2002; 50(1):33-42.
15. Engelman JA, Zhang X, Galbiati F et al. Molecular genetics of the caveolin gene family: Implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy. Am J Hum Genet 1998; 63(6): 1578-1587.
16. Razani B, EngelmanJA, Wang XB et al. Caveolin-1 nullmice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001; 276(40:38121-38138.
17. Zhao YY, Zhao YD, Mirza MK et al. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension inmice and humans through PKG nitration. J Clin Invest 2009; 1 19(7):2009-20 18.
18. Maniatis NA, Shinin V, Schraufuagel DE et al. Increased pulmonary vascular resistance and defective pulmonaryartery filling incaveolin-1 mice. Ani J Physiol Lung Cell Mol Physiol 2008; 294(5):L865-L873.
19. Mikol DD, Scherer SS, Duckett SJ et al. Schwann cell caveolin-1 expression increases during rnyelination and decreases afler axotomy. Glia 2002; 38(3):191-199.
20. Yang O, Timme TL, Naruishi K et al. Mice with cay-i gene disruption have benign stromal lesions and compromised epithelial differentiation. Exp Mol Pathol 2008; 84(2): 131-140.
21. WilliamsMC. Alveolartypelcells:molecular phenotype and development.Annu Rev Physiol 2003; 65:669-695.
22. Fuchs S.HollinsAJ. Laue M et al. Differentiation of human alveolar epithelial cells in primary culture:morphological characterization and synthesis of caveolin-1 and surfactant protein-C. Cell Tissue Res 2003; 311(1):3 1-45.
23. Wang Y, Maciejewski BS, Drouillard D et al. A role for caveolin-1 in mechanotransduction of fetal type II epithelial cells. Am J Physiol Lung Cell Mol Physiol 2010.
24. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127(3):469-480.
25. van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009; 136(19):3205-3214.
26. Galbiati F, Volonte D, Brown AM et al. Caveolin-1 expression inhibits Wnt/beta-cateninlLef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J Biol Chem 2000; 275(30):23368-23377.
27. Mucenski ML, Nation JM, Thitoff AR et al. Beta-catenin regulates differentiation of respiratory epithelial cells in vivo. Am J Physiol Lung Cell Mol Physiol 2005; 289(6):L971-L979.
28. Okamoto T, Schlegel A, Scherer PE et al. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 1998; 273(10):5419-5422.
29. Dahlin K, Mager EM, Allen L et al. Identification of genes differentially expressed in rat alveolar type I cells. Am J Respir Cell Mol Biol 2004; 31(3):309-316.
30. Mama TN. Fundamental structural aspects and features in the bioengineering of the gas exchangers: Comparative perspectives. Adv Anat Embryol Cell Biol 2002; 163:III-XII, 1-108.
31. Gold WA, Murray JF, Nadel JA, eds. Procedures in Respiratory Medicine. Philadelphia: Saunders, 2002.
32. Weibel ER. Morphological basis of alveolar-capillary gas exchange. Physiol Rev 1973; 53(2):419-495.
33. Gil J. Number and distribution of plasmalemmal vesicles in the lung. Fed Proc 1983; 42(8):2414-2418.
34. Gil J, Silage DA, McNiff JM. Distribution of vesicles in cells of air-blood banier in the rabbit. J Appl Physiol 1981; 50(2):334-340.
35. Borok Z, Liebler JM, Lubman RL et al. Na transport proteins are expressed by rat alveolar epithelial type I cells. Am J Physiol Lung Cell Mol Physiol 2002; 282(4):L599-L608.
36. Johnson MD, Widdicombe JH, Allen Let al. Alveolar epithelial type I cells contain transport proteins and transport sodium, supporting an active role for type I cells in regulation of lung liquid homeostasis. Proc Natl Acad Sci U S A 2002; 99(4):1966-1971.
37. Dobbs LG, Gonzalez R, Matthay MA et al. Highly water-permeable type I alveolar epithelial cells confer high water permeability between the airspace and vasculature in rat lung. Proc Natl Acad Sci U S A 1998; 95(6):2991-2996.
38. Newman GR, Campbell L, von Ruhland C et al. Caveolin and its cellular and subcellular immunolocalisation in lung alveolar epithelium: Implications for alveolar epithelial type I cell function. Cell Tissue Res 1999; 295(1):111-120.
39. Gumbleton M. Caveolae as potential macromolecule trafucking compartments within alveolar epithelium. Adv Drug Dcliv Rev 2001; 49(3):281-300.
40. Atwal OS, Viel L, Minhas KJ. An uptake of cationized fenitinby alveolar type I cells in airway-instilled goat lung: Distributionofanionic sites onthe epithelial surface. J Submicrosc CytolPathol 1990; 22(3):425-432.
41. Kasper M, Reimann T, Hempel U et al. Loss of caveolin expression in type I pneumocytes as an indicator of subcellular alterations during lung fibrogenesis. Histochem Cell Biol 1998; 109(1):41-48.
42. Andreeva AV, Kutuzov MA, Voyno-Yasenetskaya TA. Regulation of surfactant secretion in alveolar type II cells. Am J Physiol Lung Cell Mol Physiol 2007; 293(2):L259-L271.
43. Campbell L, Hollins AJ, Al-Eid A et al. Caveolin-1 expression and caveolae biogenesis during cell transdifferentiation in lung alveolar epithelial primary cultures. Biochem Biophys Res Commun 1999; 262(3):744-75 1.
44. Bignon J, Jaurand MC, Pinchon MC et al. Tmmunoelectron microscopic and immunochemical demonstrations of serum proteins inthe alveolar lining material of the rat lung. Am Rev Respir Dis 1976; 113(2): 109-120.
45. Kogo H, Aiba T, Fujimoto T. Cell type-specific occunence of caveolin-lalpha and -lbeta in the lung caused by expression of distinct mRNAs. J Biol Chem 2004; 279(24):25574-25581.
46. Peterson BT, Idell S, MacArthur C et al. A modified bronchoalveolar lavage procedure that allows measurement of lung epithelial lining fluid volume. Am Rev Respir Dis 1990; 141(2):314-320.
47. Peterson BT, Grifuth DE, Tate RW et al. Single-cycle bronchoalveolar lavage to determine solute concentrations in epithelial lining fluid. Am Rev Respir Dis 1993; 147(5): 1216-1222.
48. Pusch R, Kleen M, Habler O et al. Biochemical and cellular composition of alveolar epithelial lining fluid in anesthetized healthy lambs. Eur J Med Res 1997; 2(12):499-505.
49. Hastings RH, Wright JR, Albertine KH et al. Effect of endocytosis inhibitors on alveolar clearance of albumin, immunoglobulin G, and SP-A in rabbits. Am J Physiol 1994; 266(5 Pt 1):L544-L552.
50. Hastings RH, Foilcesson HG, Petersen Vet al. Cellular uptake of albumin from lungs of anesthetized rabbits. Am J Physiol 1995; 269(4 Pt 1):L453-L462.
51. Hastings RH, Foilcesson HG, Matthay MA. Mechanisms of alveolar protein clearance in the intact lung. Am J Physiol Lung Cell Mol Physiol 2004; 286(4):L679-L689.
52. John TA. Vogel SM. Minshall RD etal. Evidence for the role of alveolar epithelial gp60 in active transalveolar albumin transport in the rat lung. J Physiol 2001; 533(Pt 2):547-559.
53. Ware LB, Matthay MA. Clinicalpractice. Acutepulmonary edema. N Engl J Med 2005; 353(26):2788-2796.
54. Orfanos SE, Mavrommati I, Korovesi I et al. Pulmonary endothelium in acute lung injury: From basic science to the critically ill. Intensive Care Med 2004; 30(9):1702-1714.
55. Maniatis NA, Orfanos SE. The endothelium in acute lung injury acute respiratory distress syndrome. Cun Opin Crit Care 2008; 14(1):22-30.
56. Maniatis NA, Kotanidou A, Catraxas JD et al. Endothelial pathomechanisms in acute lung injury. Vascul Pharmacol 2008; 49(4-6):1 19-133.
57. Predescu SA, Predescu DN, Malik AB. Molecular determinants of endothelial transcytosis and their role in endothelial permeability. Am J Physiol Lung Cell Mol Physiol 2007; 293(4):L823-L842.
58. MehtaD,MalikAB. Signaling mechanisms regulating endotheial permeability. Physiol Rev 2006; 86(1):279-367.
59. Minshall RD, Malik AB. Transport across the endothelium: Regulation of endothelial permeability. Handb Exp Pharmacol 2006; (176 Pt 1):107-144.
60. Schnitzer JE, AllardJ, Oh P. NEM inhibits transcytosis, endocytosis, and capillary permeability: Implication of caveolae fusion in endothelia. Am J Physiol 1995; 268U Pt 2):H48-H55.
61. Tiruppathi C, Song W, Bergenfeldt Metal. Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J Biol Chem 1997; 272(41):25968-25975.
62. Minshall RD, Tiruppathi C, Vogel SM et al. Endothelial cell-surface gp60 activates vesicle formation and trafucking via G(i)-coupled Src kinase signaling pathway. J Cell Biol 2000; 150(5):1057-1070.
63. John TA, Vogel SM, Tiruppathi C et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 2003; 284(1):L187-L196.
64. Shajahan AN, Timblin BK, Sandoval R et al. Role of Src-induced dynamin-2 phosphorylation in caveolae-mediated endocytosis in endothelial cells. J Biol Chem 2004; 279(19):20392-20400.
65. Shajahan AN, Tiruppathi C, Smrcka AV et al. Gbetagamma activation of Src induces caveolae-mediated endocytosis in endothelial cells. J Biol Chem 2004; 279(46):48055-48062.
66. Minshall RD, Tiruppathi C, Vogel SM et al. Vesicle formation and trafucking in endothelial cells and regulation of endothelial banier function. Histochem Cell Biol 2002; 117(2):105-1 12.
67. ParkarNS, Alcpa BS, Nitsche LC et al. Vesicle formation andendocytosis: Function, machinery, mechanisms, and modeling. Antioxid Redox Signal 2009; 11(6): 1301-1312.
68. Maniatis NA, Brovkovych V, Allen SE et al. Novelmechanism ofendothelial nitric oxide synthase activation mediated by caveolae internalization in endothelial cells. Circ Res 2006; 99(8):870-877.
69. Schnitzer JE, Oh P. Aquaporin-1 in plasma membrane and caveolae provides mercury-sensitive water channels across lung endothelium. Am J Physiol 1996; 270U Pt 2):H416-H422.
70. Zhang XL, Topley N, Ito T et al. Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor compartmentalization and turnover enhances TOF-betal signaling. J Biol Chem 2005; 280(13):12239-12245.
71. Schubert W, Frank PO, Woodman SE et al. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cay-i null mice. J Biol Chem 2002; 277(42):40091-40098.
72. Miyawaki-Shimizu K, Predescu D, Shimizu J et al. siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathway. Am J Physiol Lung Cell Mol Physiol 2006; 290(2):L405-L413.
73. Sun Y, Hu O, Zhang X et al. Phosphorylation of caveolin-1 regulates oxidant-induced pulmonary vascular permeability via paracellular and transcellular pathways. Circ Res 2009; 105(7):676-685, 615 p following 685.
74. Hu U, Vogel SM, Schwartz DE et al. Intercellular adhesion molecule-i-dependent neutrophil adhesion to endothelial cells induces caveolae-mediated pulmonary vascular hyperpermeability. Circ Res 2008; 102(12):e120-e13 1.
75. Smith P, Heath D, Yacoub M et al. The ultrastructure of plexogenic pulmonary arteriopathy. J Pathol 1990; 160(2):111-121.
76. Dorfriuller P, Humbert M, Capron F et al. Pathology and aspects of pathogenesis in pulmonary arterial hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20(1):9-19.
77. Sakao S, Tatsumi K, Voelkel NF. Endothelial cells and pulmonary arterial hypertension: Apoptosis, proliferation, interaction and transdifferentiation. Respir Res 2009; 10:95.
78. Simonneau O, Robbins TM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. JAm Coll Cardiol 2009; 54U Suppl):543-554.
79. Tuder RM, Groves B, Badesch DB et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144(2):275-285.
80. Cool CD. Groshong SD. Oakey Jet al. Pulmonary hypertension: Cellular and molecular mechanisms. Chest 2005; 128(6 Suppl):5655-5715.
81. Sakao S, Taraseviciene-Stewart L, Lee JD et al. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 2005; 19(9):1 178-1180.
82. Sehgal PB, Mukhopadhyay S. Dysfunctional intracellular trafucking in the pathobiology of pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2007; 37(i):31-37.
83. Smith P, Heath D. Electron microscopy of the plexiform lesion. Thorax 1979; 34(2):177-186.
84. Heath D, Smith P, Gosney J et al. The pathology of the early and late stages of primary pulmonary hypertension. Br Heart J 1987; 58(3):204-213.
85. Geraci MW, Moore M, Gesell T et al. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: A gene microanay analysis. Circ Res 2001; 88(6):555-562.
86. Achcar RO, Demura Y, Rai PR et al. Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension. Chest 2006; 129(3):696-705.
87. Mathew R, Huang J, Shah M et al. Disruption of endothelial-cell caveolin-lalpha rafi scaffolding during development of monocrotaline-induced pulmonary hypertension. Circulation 2004; 110(11): 1499-1506.
88. Mukhopadhyay S, Xu F, Sehgal PB. Abenant cytoplasmic sequestration of eNOS in endothelial cells afler monocrotaline, hypoxia, and senescence: Live-cell caveolar and cytoplasmic NO imaging. Am J Physiol Heart Circ Physiol 2007; 292(3):H1373-H1389.
89. Jasmin JF, Mercier I, Dupuis J et al. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 2006; 1 14(9):912-920.
90. Zhao YY, Liu Y, Stan RV et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci U S A 2002; 99(17): 11375-11380.
91. Wunderlich C, Schober K, Lange SA et al. Disruption of caveolin-1 leads to enhanced nitrosative stress and severe systolic and diastolic heart failure. Biochem Biophys Res Commun 2006; 340(2):702-708.
92. Wunderlich C, Schober K, Schmeisser A et al. The adverse cardiopulmonary phenotype of caveolin-1 deficient mice is mediated by a dysfunctional endothelium. J Mol Cell Cardiol 2008; 44(5):938-947.
93. WunderlichC, SchmeisserA, Heerwagen C et al. Chronic NOS inhibition prevents adverse lung remodeling and pulmonary arterial hypertension incaveolin-1 knockoutmice. Pulm PharmacolTher 2008; 2 1(3):507-5 15.
94. Zhao YY, Malik AB. A novel insight into the mechanism of pulmonary hypertension involving caveolin-1 deficiency and endothelial nitric oxide synthase activation. Trends Cardiovasc Med 2009; 19(7):238-242.
95. Khalil N, O'Connor RN, Flanders KC et al. TOF-beta 1, but not TOF-beta 2 or TOF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: An immunohistochemical study. Am J Respir Cell Mol Biol 1996; 14(2):131-138.
96. Khalil N, O'Connor RN, Unruh 11W et al. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulm onaryfibrosis.Am J Respir Cell Mol Biol 1991; 5(2):l55-l62.
97. Khalil N, O'Connor RN, Flanders KC et al. Regulation of type II alveolar epithelial cell proliferation by TGF-beta during bleomycin-induced lung injury in rats. Am J Physiol 1994; 267(5 Pt 1):L498-L507.
98. Verma S, SlutskyAS. Idiopathic pulmonary fibrosis-new insights. N Engl J Med 2007; 356(13): 1370-1372.
99. Varga J, Abraham D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J Clin Invest 2007; 1 17(3):557-567.
100. Del Galdo F, Lisanti MP, Jimenez SA. Caveolin-1, transforming growth factor-betareceptor internalization and the pathogenesis of systemic sclerosis. Cun Opin Rheumatol 2008; 20(6):7 13-719.
101. Drab M, Verkade P, Elger M et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001; 293(5539):2449-2452.
102. Le Saux O, Teeters K, Miyasato S et al. The role of caveolin-1 in pulmonary matrix remodeling and mechanical properties. Am J Physiol Lung Cell Mol Physiol 2008; 295(6):L1007-L1017.
103. Murata T, Lin MI, Huang Yet al. Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. J Exp Med 2007; 204(10):2373-2382.
104. Odajima N, Betsuyaku T, Nasuhara Y et al. Loss of caveolin-1 in bronchiolization in lung fibrosis. J Histochem Cytochem 2007; 55(9):899-909.
105. Tourkina E, Gooz P, Pannu Jet al. Opposing effects of protein kinase Calpha and protein kinase Cepsilon on collagen expression by human lung fibroblasts are mediated via MEKJERK and caveolin-1 signaling. J Biol Chem 2005; 280U4):13879-13887.
106. Wang XM, Zhang Y, Kim HP et al. Caveolin-1: A critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med 2006; 203(13):2895-2906.
107. Del Galdo F, Sotgia F, de Almeida CJ et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: Crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008; 58(9):2854-2865.
108. Tourkina E, Richard M, Gooz P et al. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 2008; 294(5):L843-L861.
109. Chen YG. Endocytic regulation of TGF-beta signaling. Cell Res 2009; 19(1):58-70.
110. Hayes S, Chawla A, Corvera S. TGF beta receptor internalization into EEA1-enriched early endosomes: Role in signaling to Smad2. J Cell Biol 2002; 158(7):1239-1249.
111. Di Guglielmo GM, Le Roy C, Goodfellow AF et al. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol 2003; 5(5):410-421.
112. Runyan CE, Schnaper HW, Poncelet AC. The role of internalization in transforming growth factor betal-induced Smad2 associationwith Smad anchor forreceptor activation (SARA) and Smad2-dependent signaling in human mesangial cells. J Biol Chem 2005; 280(9):8300-8308.
113. Bousquet J, Jeffery PK, Busse WW et al. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161(5):1720-1745.
114. Camoretti-Mercado B. Targeting the airway smooth muscle for asthma treatment. Transl Res 2009; 154(4):165-174.
115. MurphyDM, O'BymePM. Recent advances in the pathophysiology of asthma. Chest 2010; 137(6): 1417-1426.
116. Halayko AJ, Tran T, Gosens R. Phenotype and functional plasticity of airway smooth muscle: Role of caveolae and caveolins. Proc Am Thorac Soc 2008; 5(1):80-88.
117. Owens GK. Regulation of differentiation of vascular smoothmuscle cells. Physiol Rev 1995; 75(3):487-5 17.
118. Owens GK, Kumar MS, WamhoffBR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004; 84(3):767-801.
119. Hirst SJ, Twort CH, Lee TH. Differential effects of extracellular matrix proteins on human airway smooth muscle cell proliferation and phenotype. Am J Respir Cell Mol Biol 2000; 23(3):335-344.
120. Dekkers BG, Schaafsma D, Tran T et al. Insulin-induced laminin expression promotes a hypercontractile airway smooth muscle phenotype. Am J Respir Cell Mol Biol 2009; 41(4):494-504.
121. Dekkers BG, Schaafsma D, Nelemans SA et al. Extracellular matrix proteins differentially regulate airway smooth muscle phenotype and function. Am J Physiol Lung Cell Mol Physiol 2007; 292(6):L1405-L1413.
122. Schaafsma D, McNeill KD, Stelmack GL et al. Insulin increases the expression of contractile phenotypic markers in airway smooth muscle. Am J Physiol Cell Physiol 2007; 293(1):C429-C439.
123. Peterson TE, Guicciardi ME, Gulati Ret al. Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol 2003; 23(9):1521-1527.
124. Thyberg J, Roy J, Tran PK et al. Expression of caveolae on the surface of rat arterial smooth muscle cells is dependent on the phenotypic state of the cells. Lab Invest 1997; 77(1):93-101.
125. Zhang Y, Peng F, Gao B et al. Mechanical Strain-Induced RhoA Activation Requires NADPH Oxidase-Mediated ROS Generation in Caveolae. Antioxid Redox Signal 2010.
126. Peng F, Zhang B, Wu D et al. TGFbeta-induced RhoA activation and fibronectin production in mesangial cells require caveolae. Am J Physiol Renal Physiol 2008; 295(1):F153-F164.
127. Somara S, Gilmont RR, Martens JRet al. Ectopic expression of caveolin-1 restores physiological contractile response of agedcolonic smoothmuscle. Am J Physiol Gastrointest Liver Physiol 2007; 293(1):G240-G249.
128. Hunter I, Nixon OF. Spatial compartmentalization of tumor necrosis factor (TNF) receptor 1-dependent signaling pathways inhumanairway smooth muscle cells. Lipidrafis are essential for TNF-alpha-mediated activation of RhoA but dispensable for the activation of the NF-kappaB and MAPK pathways. J Biol Chem 2006; 281(45):34705-347 15.
129. Gosens R, Dueck O, Gerthoffer WT et al. p42 p44 MAP kinase activation is localized to caveolae-free membrane domains in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2007; 292(5): Li163-Li172.
130. Le Saux CJ, Teeters K, Miyasato SKet al. Down-regulation of caveolin-1, an inhibitor of transforming growth factor-beta signaling, in acute allergen-induced airway remodeling. J Biol Chem 2008; 283(9):5760-5768.
131. Mercer J, Schelhaas M, Helenius A. Virus entry by endocytosis. Annu Rev Biochem 79:803-833.
132. Zaas DW, Duncan MJ, Li O et al. Pseudomonas invasion of type I pneumocytes is dependent on the expression and phosphorylation of caveolin-2. J Biol Chem 2005; 280(6):4864-4872.
133. Millan J, Hewlett L, Glyn M et al. Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola-and F-actin-rich domains. Nat Cell Biol 2006; 8(2): 113-123.
134. Tiruppathi C, Shimizu J, Miyawaki-Shimizu K et al. Role ofNF-kappaB-dependent caveolin-1 expression in the mechanism of increased endothelial permeability induced by lipopolysaccharide. J Biol Chem 2008; 283(7):4210-4218.
135. Hatakeyama T, Pappas PJ, Hobson RW 2nd et al. Endothelial nitric oxide synthase regulates microvascular hyperpermeability in vivo. J Physiol 2006; 574(Pt 1):275-281.
136. Sessa WC. eNOS at a glance. J Cell Sci 2004; 1 17(Pt 12):2427-2429.
137. Zhou X, T-Ie P. Endothelial [Ca2+]i and caveolin-1 antagonisticallyregulate eNOS activity andmicrovessel permeability in rat venules. Cardiovasc Res 87(2):340-347.
138. Bucci M, Gratton JP, Rudic RD et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 2000; 6(12):1362-1367.
139. Ganean S, Gao XP, BrovkovychV et al. Caveolin-1 regulates NF-kappaB activation and lung inflammatory response to sepsis induced by lipopolysaccharide. J Immunol 2006; 177(7):4853-4860.
140. Mirza MK, Yuan J, Gao XP et al. Caveolin-1 deficiency dampens Toll-like receptor 4 signaling through eNOS activation. Am J Pathol 176(5):2344-2351.
141. Medina FA, de Almeida CJ, Dew E et al. Caveolin-1-deficient mice show defects in innate immunity and inflammatory immune response during Salmonella enterica serovar Typhimurium infection. Infect Immun 2006; 74(12):6665-6674.
142. Medina FA, Cohen AW, de Almeida CJ et al. Immune dysfunction in caveolin-1 null mice following infection with Trypanosoma cruzi (Tulahuen strain). Microbes Infect 2007; 9(3):325-333.
143. Feng H, Guo L, Song Z et al. Caveolin-1 protects against sepsis by modulating inflammatory response, alleviating bacterial burden, and suppressing thymocyte apoptosis. J Biol Chem 285(33):25 154-25160.
144. Li J, Scherl A, Medina F et al. Impaired phagocytosis in caveolin-1 deficient macrophages. Cell Cycle 2005; 4(11):1599-1607.
145. Hu O, Ye RD, Dinauer MC et al. Neutrophil caveolin-1 expression contributes to mechanism of lung inflammation and injury. Am J Physiol Lung Cell Mol Physiol 2008; 294(2):L178-L186.
146. Oakley FD, Smith RL, Engelhardt JF. Lipid rafts and caveolin-1 coordinate interleukin-ibeta (IL-lbeta)-dependent activation of NFkappaB by controlling endocytosis of Nox2 and IL-ibeta receptor 1 from the plasma membrane. J Biol Chem 2009; 284(48):33255-33264.
147. Majkova Z, Smart E, Toborek M et al. Up-regulation of endothelial monocyte chemoattractant protein-i by coplanar PCB77 is caveolin-1-dependent. Toxicol Appl Pharmacol 2009; 237(1):1-7.
148. Wang L, Lim EJ, Toborek M et al. The role of fatty acids and caveolin-1 in tumor necrosis factor alpha-induced endothelial cell activation. Metabolism 2008; 57(10): 1328-1339.
149. Wang XM, Kim HP, NakahiraK et al. The heme oxygenase-1 carbon monoxide pathway suppresses TLR4 signaling by regulating the interaction of TLR4 with caveolin-1. J Immunol 2009; 182(6):3809-3818.
150. Schwartz AM, Henson DE. Diagnostic surgical pathology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132(3 Suppl):785-935.
151. Stinchcombe TE, Socinski MA. Cunent treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 2009; 6(2):233-241.
152. Masson RJ, Broaddus VC, Munay JF et al. Murray and Nadel's Textbook of Respiratory Medicine, 4th edition. Philadelphia: Saunders, 2005.
153. JettJR, Schild SE, Keith RLetal. Treatment ofnon-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132(3 Suppl):2665-2765.
154. Glenney JR Jr. Tyrosine phosphorylation of a 22-kDa protein is conelated with transformation by Rous sarcoma virus. J Biol Chem 1989; 264(34):20163-20166.
155. Glenney JR Jr., Soppet D. Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc Natl Acad Sci USA 1992; 89(21):10517-10521.
156. Glenney JR Jr., Zokas L. Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol 1989; 108(6):2401-2408.
157. Koleske AJ, Baltimore D, Lisanti MP. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 1995; 92(5):1381-1385.
158. An SS, Bai TR, Bates JH et al. Airway smooth muscle dynamics: A common pathway of airway obstruction in asthma. Eur Respir J 2007; 29(5):834-860.
159. Hulit J, Bash T, Fu Metal. The cyclin Dl gene is transcriptionally repressed by caveolin-1. J Biol Chem 2000; 275(28):21203-21209.
160. Gratton JP, Lin MI, Yu J et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 2003; 4(1):31-39.
161. Racine C, Belanger M, Hirabayashi H et al. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem Biophys Res Commun 1999; 255(3):580-586.
162. Wikman H, Kettunen E, Seppanen JK et al. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA anay. Oncogene 2002; 21(37):5804-5813.
163. Wikman H, Seppanen JK, Sarhadi VK et al. Caveolins as tumour markers in lung cancer detected by combined use of cDNA and tissue microanays. J Pathol 2004; 203(1):584-593.
164. Sunaga N, Miyajima K, Suzuki M et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res 2004; 64(12):4277-4285.
165. Ho CC, Huang PH, Huang HY et al. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 2002; 161(5): 1647-1656.
166. Huang J. Kaminski PM. Edwards JG et al. Pynolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline- induced pulmonary artery hypertension. Am J Physiol Lung Cell Mol Physiol 2008; 294(6):L1250-L1259.
167. Joshi B, Strugnell SS, Goetz JG et al. Phosphorylated caveolin-1 regulates Rho ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res 2008; 68(20):8210-8220.
168. Bonuccelli G, Casimiro MC, Sotgia F et al. Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem celllmetastasis-associated gene signature. Am J Pathol 2009; 174(5):1650-1662.
169. Belanger MM, Gaudreau M, Roussel E et al. Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells. Cancer Biol Ther 2004; 3(10):954-959.
170. Belanger MM, Roussel E, Couet J. Up-regulationofcaveolin expressionby cytotoxic agents in drug-sensitive cancer cells. Anticancer Drugs 2003; 14(4):281-287.